natrunix
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 22, 2021 (NCT05099510)
Timeline
Indications
Mechanism of action
SLC12A3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06590090 | Phase 2 | Sep 15, 2024 | XBiotech, Inc. |
| NCT06526377 | Phase 2 | Aug 15, 2024 | XBiotech, Inc. |
| NCT05363917 | Phase 2 | Jun 15, 2022 | XBiotech, Inc. |
| NCT05363891 | Phase 2 | Jun 15, 2022 | XBiotech, Inc. |
| NCT05099510 | Phase 1 | Nov 22, 2021 | BioBehavioral Research of Austin, XBiotech, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| XBiotech, Inc. | For profit | 5 | 5 | 2 | 2021 |
| BioBehavioral Research of Austin | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1